Company Description
AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States.
Its flagship products are Ampligen (rintatolimod), a drug of large macromolecular double-stranded ribonucleic acid molecules to treat chronic fatigue syndrome; and Alferon N Injection (Interferon alfa), a purified, natural-source, glycosylated, multi-species alpha interferon product for the treatment of genital warts.
The company is also developing Ampligen for potential treatment of pancreatic, renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as for myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions.
The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019.
AIM ImmunoTech Inc. was incorporated in 1966 and is headquartered in Ocala, Florida.
| Country | United States |
| Founded | 1966 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 23 |
| CEO | Thomas Equels |
Contact Details
Address: 2117 SW Highway 484 Ocala, Florida 34473 United States | |
| Phone | 352 448 7797 |
| Website | aimimmuno.com |
Stock Details
| Ticker Symbol | AIM |
| Exchange | NYSEAMERICAN |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 946644 |
| CUSIP Number | 00901B105 |
| ISIN Number | US00901B3033 |
| Employer ID | 52-0845822 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Thomas K. Equels Esq., J.D., M.S. | Executive Vice Chairman, Chief Executive Officer and President |
| Robert Dickey IV, B.A., M.B.A. | Chief Financial Officer |
| Peter W. Rodino III, Esq., J.D. | Chief Operating Officer, Executive Director of Governmental Relations, General Counsel and Secretary |
| Ann Marie E. Coverly | Director of Administration and Human Resources and Deputy Investor Relations Coordinator |
| Dr. Christopher Nicodemus FACP, M.D. | Member of Scientific Advisory Board and Consulting Science Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 5, 2026 | 8-K | Current Report |
| Jan 29, 2026 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| Jan 23, 2026 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| Jan 20, 2026 | 8-K | Current Report |
| Jan 12, 2026 | 8-K | Current Report |
| Dec 17, 2025 | 8-K | Current Report |
| Dec 12, 2025 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Nov 19, 2025 | 8-K | Current Report |
| Nov 17, 2025 | 10-Q | Quarterly Report |
| Nov 17, 2025 | NT 10-Q | Notification of inability to timely file Form 10-Q or 10-QSB |